Concepedia

Ahmed A. Samatar

AA

Statistics

Publications

21

Citations

2.2K

H-Index

17

Active since

1995

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

The University of Texas MD Anderson Cancer Center

Roswell Park Comprehensive Cancer Center

University of North Carolina at Chapel Hill

University of Pennsylvania

Ahmed A. Samatar is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, drug discovery, and tumor biology.

ORCID

Top concepts

Publications per year

1995–2025

21

Publications

21

Discovery of a Novel ERK Inhibitor with Activity in Models of Acquired Resistance to BRAF and MEK Inhibitors

Erick J. Morris, Sharda Jha, Clifford R. Restaino et al. · Cancer Discovery · 2013 · 673 citations · Full text

, , +20

Tunable-Combinatorial Mechanisms of Acquired Resistance Limit the Efficacy of BRAF/MEK Cotargeting but Result in Melanoma Drug Addiction

Gatien Moriceau, Willy Hugo, Aayoung Hong et al. · Cancer Cell · 2015 · 345 citations · Full text

, , +9

Long-Term ERK Inhibition in KRAS-Mutant Pancreatic Cancer Is Associated with MYC Degradation and Senescence-like Growth Suppression

Tikvah K. Hayes, Nicole F. Neel, Chaoxin Hu et al. · Cancer Cell · 2015 · 271 citations · Full text

, , +10

Identification of overexpression of orphan G protein-coupled receptor GPR49 in human colon and ovarian primary tumors

Terrill K. McClanahan, Sandra Koseoglu, Kathleen B. Smith et al. · Cancer Biology & Therapy · 2006 · 181 citations · Full text

Development of MK-8353, an orally administered ERK1/2 inhibitor, in patients with advanced solid tumors

Stergios J. Moschos, Ryan J. Sullivan, Wen-Jen Hwu et al. · JCI Insight · 2018 · 145 citations · Full text

1–5 of 21